All News

A new study of a circulating tumor DNA-based screening test revealed promising sensitivity and specificity for for CRC, but only 12.5% sensitivity for advanced neoplasia.

ASCO 2025. Elinzanetant significantly reduced the frequency of VMS vs placebo in women on endocrine therapy for treatment or prevention of HR+ breast cancer.

Nasus Pharma says promising phase 2 results for FMXIN002 show statistically significantly faster absorption than traditional autoinjectors and are published in global journal.

Lyra Pharmaceuticals designed the implant, which provides 6 months of continuous delivery of the anti-inflammatory mometasone furoate.

Your daily dose of the clinical news you may have missed.

Preview of 10 new studies on managing atopic dermatitis, including biologics, treatment barriers, and innovative care strategies for clinicians.

Interim results from COURAGE trial suggest combining semaglutide with muscle-preserving antibodies significantly enhances fat loss while preserving lean mass in obesity treatment.

Research reveals that the quality of foods in low-carb and low-fat diets significantly impacts heart health, emphasizing whole, plant-based options.

Moderna's mRNA-1283 vaccine gains FDA approval for high-risk groups, following a significant shift in COVID-19 vaccination guidelines by federal health agencies.

Your daily dose of the clinical news you may have missed.

Only about 75% of people with a positive result on a stool-based test for colorectal cancer complete screening with a colonoscopy. Fendrick "won't rest" until it's 90%.

Mark Fendrick, MD, thinks that right now, the relative accuracy of blood-based tests for CRC compared with available alternatives is not quite comparable. He explains.

The AI model showed high accuracy in detecting body parts and eczema areas, with strong correlation to physician assessments, researchers reported.

Adults with both HTN and T2D had more than twice the risk of all-cause mortality and nearly three times the risk of cardiovascular mortality, according to new data.

With a population goal of having 80% to 90% of age-eligible Americans screened for colorectal cancer, colonoscopy can not be the initial test for everyone, Fendrick emphasizes.

Treatment goals for atopic dermatitis among youth are diverse, emphasizing the need for tailored approaches based on age and disease severity, a new study suggests.

Itepekimab performed well in the phase 3 AERIFY-1 trial but fell short of anticipated outcomes in AERIFY-2, prompting further analysis after the mixed results.

Your daily dose of the clinical news you may have missed.